Boston Scientific Corporation $BSX Shares Purchased by Merit Financial Group LLC

Merit Financial Group LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX) by 4.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 141,196 shares of the medical equipment provider’s stock after buying an additional 6,268 shares during the quarter. Merit Financial Group LLC’s holdings in Boston Scientific were worth $13,785,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Steph & Co. acquired a new stake in shares of Boston Scientific in the third quarter worth approximately $25,000. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at approximately $26,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Sound Income Strategies LLC lifted its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific during the second quarter worth approximately $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.2%

BSX opened at $95.98 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The stock has a market capitalization of $142.28 billion, a P/E ratio of 51.32, a P/E/G ratio of 1.93 and a beta of 0.67. The business has a 50 day simple moving average of $98.36 and a 200-day simple moving average of $101.05.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business posted $0.63 earnings per share. Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 93,095 shares of company stock worth $9,305,450 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Robert W. Baird raised their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Barclays lifted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Leerink Partners increased their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Finally, UBS Group restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $124.85.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.